Equashield, a provider of Closed System Transfer Devices for the handling of hazardous drugs, has broken ground to mark the beginning of the construction of a new manufacturing plant.
The company will invest an estimated $30 million to build the new plant to meet the growing market demand for manual and automated hazardous drug compounding devices.
The new manufacturing facility will be built on a 3 acre plot with an option to expand by another 1.5 acres.
The new plant will expand the manufacturing capabilities of Equashield, Equashield’s flagship CSTD, as well as the new Equashield Pro closed system drug compounding robot, first unveiled at the ASHP Midyear meeting.
Marino Kriheli, co-founder of Equashield, says: “As Equashield continues to expand into new international markets, this plant will provide the capacity to significantly expand our product portfolio, while enabling us to fulfill worldwide need for current and future CSTD demand.
“With these enhanced capabilities Equashield can continue to make a difference for those who work with and around hazardous drugs.”
Construction of the 112,000-square foot building is expected to complete in July 2019.
It will include a 20,000-square foot cleanroom space, incorporating the HVAC variable refrigerant flow system for cooling and air conditioning.
Production will be fully automated, from raw materials entry to packaging and palletizing, to preserve sterility of products.